



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/809,946
	Filing Date	March 25, 2004
	First Named Inventor	Guy Brenchley
	Group Art Unit	1624
	Examiner Name	Not yet assigned
	Attorney Docket Number	VPI/02-118 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
DR	A1	US2003/119856 A1	6/26/2003	Harrington et al.			
	US	2003/0119856	A1	Cochran et al.			

CG
6/15

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
DR	B1	WO	00/78731 A1	Celltech Chiroscience Ltd.	28 December 2000		
DR	B2	WO	97/19065 A1	Celltech Therapeutics Ltd.	29 May 1997		
DR	B3	WO	02/096905 A1	Vertex Pharmaceuticals, Inc.	5 December 2002		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
DR	C1	Strawn, Laurie et al., "Tyrosine Kinases in Disease: Overview of Kinase Inhibitors as Therapeutic Agents and Current Drugs in Clinical Trials", Expert Opinion on Investigational Drugs, Vol. 7, No. 4, Pages 553-573, (1998).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Deepak Rao/	Date Considered	08/03/2006
-------------------------------	--------------	----------------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.